Explore the Effect of Bitter Melon Peptides on Glycemic Control and Metabolic Indicators in Diabetic Patients
NCT ID: NCT06970834
Last Updated: 2025-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
160 participants
INTERVENTIONAL
2025-05-27
2026-03-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* the regulatory effects of bitter melon peptides on glycemic variability
* impact on glycemic and metabolic indicators Researchers will compare bitter melon peptides to a placebo (a look-alike capsule that contains Microcrystalline Cellulose) to see if bitter melon peptides works to stabilizing blood glucose.
Participants will:
* Take bitter melon peptides or a placebo every day for 12 weeks
* Visit the clinic on day 0, day 7, day 28 and day 84 for checkups and tests
* Glucose levels were monitored continuously by CGMs in the first 7 days and fasting blood samples were drawn at first visit (day0), third visit (day 28) and fourth visits (day 84)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Bitter Melon on Cardiometabolic Health
NCT05540405
The Effect of Momordica Charantia Supplementation on Blood Glucose Levels
NCT04090788
The Effect of Long-term Momordica Charantia Supplementation on Blood Glucose Levels
NCT05215210
Interaction of Melatonin and MTNR1B Genotype on Glucose Control - Study 1
NCT02642640
Hypoglycemic Efficacy of Greenyn Momordica Charantia Extracts in Diabetic Subjects
NCT03151837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
bitter melon peptides
Bitter melon peptide contains various active substances such as bitter melon saponins and bitter melon polysaccharides.
bitter melon peptides
Momordica charantia extract
Placebo group
The placebo capsule containing microcrystalline cellulose. The placebo is identical in appearance, color, and dosage schedule to the intervention product, but does not contain any active ingredients.
bitter melon peptides
Momordica charantia extract
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bitter melon peptides
Momordica charantia extract
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China Medical University, Taiwan
OTHER
Changhua Christian Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
PEI-YUNG LIAO
Chief of Division of Endocrinology and Metabolism, Department of Internal Medicine
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCH IRB 250121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.